Innate Pharma (NASDAQ:IPHA) Price Target Raised to $9.00

Innate Pharma (NASDAQ:IPHA) had its target price increased by BTIG Research from $8.00 to $9.00 in a report published on Wednesday morning, MarketBeat Ratings reports. BTIG Research currently has a buy rating on the stock.

Several other equities analysts have also issued reports on IPHA. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a report on Tuesday. Weiss Ratings raised Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. HC Wainwright upped their price objective on Innate Pharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday. Leerink Partners raised Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price objective on the stock in a research report on Tuesday. Finally, UBS Group reiterated a “buy” rating on shares of Innate Pharma in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $6.67.

Innate Pharma Trading Down 14.2%

Shares of Innate Pharma stock opened at $2.18 on Wednesday. The firm’s 50-day moving average is $1.84 and its two-hundred day moving average is $1.68. Innate Pharma has a 1 year low of $1.17 and a 1 year high of $2.71.

Institutional Trading of Innate Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new position in Innate Pharma during the 4th quarter valued at about $36,000. OLD Mission Capital LLC acquired a new stake in Innate Pharma in the fourth quarter worth about $50,000. Finally, Jane Street Group LLC purchased a new stake in shares of Innate Pharma during the fourth quarter worth about $162,000. Hedge funds and other institutional investors own 0.16% of the company’s stock.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.